Skip to main content

Michael D. Maline

Member

[email protected]

+1.212.692.6860

Share:

Michael is a leading corporate lawyer with significant experience representing global investment banks, issuers, and investors in public and private capital markets transactions. He regularly advises clients in initial public offerings, follow-on offerings, private placements of equity and debt securities, and other transactions — focusing on cross-border offerings for foreign issuers selling securities into the United States as well as offerings for US companies.

He brings a deep understanding of alternative financing techniques such as confidentially marketed public offerings (CMPOs), bought deals, registered direct offerings (RDs), private investments in public equity (PIPEs), special purpose acquisition companies (SPACs), and at-the-market offerings (ATMs) to his work with clients across a wide range of industries, from growth sectors such as life sciences and technology to media and consumer products.

Michael also advises clients on corporate and securities compliance and reporting matters.

Education

  • Tulane Law School (JD, magna cum laude)
  • The Johns Hopkins University (BA)

Experience

Initial Public Offering Representations:

  • BTIG, LLC as lead underwriter in Gain Therapeutics, Inc.’s initial public offering.
  • Citigroup Global Markets as lead underwriter in Arsanis, Inc.’s initial public offering.
  • Cowen and Company as lead underwriter in MaxCyte, Inc.’s initial public offering.  
  • JMP Securities as lead underwriter in Summit Therapeutics PLC’s (UK) initial public offering.
  • J.P. Morgan and Stifel as joint global coordinators and joint book-running managers in RenalytixAI plc’s (UK) initial public offering.
  • J.P. Morgan as lead underwriter in G1 Therapeutics, Inc.’s initial public offering.  
  • J.P. Morgan as lead underwriter in Intrexon Corporation’s initial public offering.
  • Piper Jaffray & Co. as lead underwriter in Innocoll AG’s (Germany) initial public offering.  
  • Piper Jaffray & Co. as lead underwriter in Itamar Medical Ltd.’s (Israel) initial U.S. public offering.
  • Piper Jaffray & Co. as lead underwriter in MDxHealth SA’s (Belgium) initial public offering.
  • SVB Leerink as lead underwriter in Centogene N.V.’s (The Netherlands) initial public offering.  

Follow-On Offering Representations:

  • BofA Securities as lead underwriter in BeyondSpring Inc.’s $86 million follow-on offering.
  • Cowen and Company as lead underwriter in Protara Inc.’s $150 million concurrent public offering of common and preferred stock.
  • Credit Suisse as lead underwriter in Centogene N.V.’s (The Netherlands) $50 million primary and secondary public offering.
  • Deutsche Bank Securities Inc. as lead underwriter in Orient-Express Hotels Ltd.’s three public offerings raising aggregate gross proceeds of $400 million.
  • Goldman Sachs & Co. as lead underwriter in two follow-on offerings for Sarepta Therapeutics, Inc. raising aggregate gross proceeds of $825 million.
  • Goldman Sachs & Co. as lead underwriter in Krystal Biotech, Inc.’s $100 million follow-on offering.
  • Jefferies as lead underwriter in Solutia Inc.’s $160 million follow-on offering.
  • JMP Securities as lead underwriter in Flamel Technologies, S.A.’s (France) $105 million follow-on offering.
  • J.P. Morgan as lead underwriter in NPS Pharmaceuticals, Inc.’s $87 million follow-on offering.
  • Morgan Stanley as lead underwriter in a $162 million public offering by existing shareholders of Horizon Pharma, Inc.
  • Piper Jaffray & Co. as sole underwriter in Global Eagle Entertainment Inc.’s $190 million follow-on offering.
  • William Blair & Company as lead underwriter in Viking Therapeutics, Inc.’s $175 million follow-on offering.

Alternative Transaction Representations:

  • BTIG as sole underwriter in two “bought deals” for Cerus Corporation.
  • Cowen and Company as lead placement agent in Invitae Corporation’s $275 million PIPE to finance its acquisition of Archer DX.
  • Cowen and Company as lead placement agent in Horizon Pharma Inc.’s $150 million 5% convertible note offering.
  • Deutsche Bank Securities as placement agent in a $600 million registered direct offering for The St. Joe Company.
  • Deutsche Bank Securities Inc. as lead placement agent in Smith & Wesson Holding Corporation’s two registered direct offerings.
  • Jefferies as lead placement agent in TFF Pharmaceuticals, Inc.’s $26 million PIPE.
  • Piper Sandler & Co. as sole placement agent in Humacyte, Inc.’s $175 million PIPE to finance its business combination with Alpha Healthcare Acquisition Corp.

Recognition & Awards

  • Featured multiple times as a New York "Super Lawyer" by Thomson Reuters
  • Order of the Coif